AbbVie | ABBV - Cash And Equivalent

Stock Price
217.11
Daily Change
-8.55 -3.79%
Monthly
-1.39%
Yearly
13.23%
Q1 Forecast
216.14

AbbVie reported $5.63B in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.63B 838M Sep/2025
Abbott USD 7.51B 560M Sep/2025
ALKERMES USD 616.45M 95.25M Sep/2025
Amgen USD 9.13B 316M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Biogen USD 3.86B 1.1B Sep/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Bristol-Myers Squibb USD 15.73B 3.13B Sep/2025
Eisai JPY 285.38B 19.82B Jun/2025
Eli Lilly USD 9.79B 6.42B Sep/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
J&J USD 18.23B 10.35B Sep/2025
Medtronic USD 1.28B 9M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Neurocrine Biosciences USD 340.2M 76.2M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pacira USD 147.59M 152.89M Sep/2025
Perrigo USD 432.1M 22.1M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
UCB EUR 1.57B 1.14B Dec/2024
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
United Therapeutics USD 1.34B 253M Sep/2025
Vertex Pharmaceuticals USD 6.29B 95.8M Sep/2025
Zoetis USD 2.08B 649M Sep/2025